Nicholas Augustinos - DexCom Independent Director
| DXCM Stock | USD 130.71 3.59 2.67% |
Director
Mr. Nicholas Augustinos serves as Independent Director of DexCom Inc., since November 20, 2009. Since December 2015 through December 2018, Mr. Augustinos has served as President and CEO of Aver, Inc., a company specializing in bundled payment and analytics solutions. He served on the Board of Directors of Aver since September 2014. Starting January 2019 he was elected Chairman of the Board of Directors of Aver. From November 2011 until December 2015, Mr. Augustinos worked for Cardinal Health, Inc. as its Senior Vice President for Health Information Services and Strategy. From March 2005 through October 2011, Mr. Augustinos worked for Cisco Systems, Inc., a networking company. At Cisco, he held various positions, including Director of Ciscos Internet Business Solutions Group, Senior Director, Global Healthcare Solutions Group, and Senior Director of Global Healthcare Operations. In January 2015, Mr. Augustinos was appointed to the Board of Directors of the California Health Care Foundation, which seeks to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. Prior to CHCF he served on the Board of Directors of the SCAN Foundation, an organization dedicated to advancing the development of a sustainable continuum of quality care for seniors, from June 2011 until December 2014. Mr. Augustinos served on the Board of Directors of Audax Health, now Rally, from March 2012 until February 2014. With a 31year career in healthcare and healthcare technology, Mr. Augustinos has broad managerial, consulting and business development experience in the private and public sectors since 2009.
| Age | 59 |
| Tenure | 15 years |
| Address | 6340 Sequence Drive, San Diego, CA, United States, 92121 |
| Phone | 858 200 0200 |
| Web | https://www.dexcom.com |
DexCom Management Efficiency
The company has return on total asset (ROA) of 0.0641 % which means that it generated a profit of $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2578 %, meaning that it created $0.2578 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Intangible Assets are very stable compared to the past year. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to 0.09, while Debt To Assets are likely to drop 0.41.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Francis | Mettler Toledo International | 52 | |
| Frances Arnold | Illumina | 61 | |
| Paul Clark | Agilent Technologies | 72 | |
| Mala Anand | Agilent Technologies | 53 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| WahHui Chu | Mettler Toledo International | 69 | |
| Daniel Bradbury | Illumina | 56 | |
| George Scangos | Agilent Technologies | 72 | |
| Gary Guthart | Illumina | 52 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Tyler Jacks | Thermo Fisher Scientific | 59 | |
| Aaref Hilaly | Guardant Health | 46 | |
| Heidi Fields | Agilent Technologies | 60 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Hans Maerki | Mettler Toledo International | 71 | |
| Connie Harvey | Mettler Toledo International | 52 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Susan Siegel | Illumina | 57 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 |
DexCom Inc Leadership Team
Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Topol, Independent Director | ||
| Lanny Roper, CFO, Vice President | ||
| Shelly Selvaraj, Senior Officer | ||
| Matthew Dolan, Corporate Strategy | ||
| Patrick Murphy, Chief Compliance Officer, Vice President General Counsel | ||
| Mark Foletta, Independent Director | ||
| Jonathan Lord, Independent Chairman of the Board | ||
| Jacob Leach, Executive COO | ||
| Donald Abbey, Executive Vice President Quality and Information Technology | ||
| Jay Skyler, Independent Director | ||
| Jake Leach, Senior Vice President of Research and Development | ||
| Jorge Valdes, Chief Technical Officer and Executive VP | ||
| Paul Flynn, Ex Revenue | ||
| Kevin Sayer, CEO and President and Director | ||
| Terrance Gregg, Executive Chairman | ||
| Michael Brown, Executive Officer | ||
| Richard Doubleday, Senior Vice President - Worldwide Sales and Marketing | ||
| Jess Roper, CFO and Sr. VP | ||
| Sean Christensen, Director Relations | ||
| Quentin Blackford, CFO | ||
| Kevin Sun, Interim CFO | ||
| Nicholas Augustinos, Independent Director | ||
| Leverne Marsh, Executive Marketing | ||
| Jeffrey Moy, Senior Vice President - Operations | ||
| Jereme Sylvain, CFO VP | ||
| Heather Ace, Senior Vice President Human Resources | ||
| Girish Naganathan, Executive CTO | ||
| John Lister, Senior Vice President General Counsel | ||
| Richard Collins, Independent Director | ||
| Sadie Stern, Executive Officer | ||
| Barbara Kahn, Independent Director | ||
| Steven Pacelli, Executive VP of Strategy and Corporate Devel. | ||
| Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs | ||
| Steven Altman, Independent Director |
DexCom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 51.64 B | ||||
| Shares Outstanding | 385.52 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 99.59 % | ||||
| Number Of Shares Shorted | 14.57 M | ||||
| Price To Earning | 245.31 X |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving against DexCom Stock
| 0.66 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
| 0.64 | IVP | Inspire Veterinary | PairCorr |
| 0.59 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
| 0.54 | AHG | Akso Health Group | PairCorr |
| 0.47 | DYNT | Dynatronics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.